General Information of Drug (ID: DR3200)
Drug Name
BIIB074
Synonyms CNV1014082; BC600719; HY-12796; B5927; (5R)-5-(4-[2-
Indication Bipolar disorder [ICD11: 6A60] Phase 2 [1]
Lumbosacral radiculopathy [ICD11: ICD11: 8B93] Phase 2 [2]
Trigeminal neuralgia [ICD11: ICD11: 8B82] Phase 2 [3]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 314.4 Topological Polar Surface Area 64.4
Heavy Atom Count 23 Rotatable Bond Count 5
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 4
Cross-matching ID
PubChem CID
16046068
CAS Number
934240-30-9
TTD Drug ID
D0OX9F
Formula
C18H19FN2O2
Canonical SMILES
C1C[C@H](N[C@H]1C2=CC=C(C=C2)OCC3=CC=CC=C3F)C(=O)N
InChI
InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1
InChIKey
JESCETIFNOFKEU-SJORKVTESA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
BIIB074 metabolite M10 DM017219 N. A. Unclear - Unclear 1 [4]
BIIB074 metabolite M13 DM017218 N. A. Conjugation - N-carbamoyl glucuronidation 1 [4]
BIIB074 metabolite M14 DM016264
67508639
Hydrolysis - Amide hydrolysis 1 [4]
BIIB074 metabolite M16 DM016263
67508374
Hydrolysis - Amide hydrolysis 2 [4]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR008290 BIIB074 BIIB074 metabolite M14 Hydrolysis - Amide hydrolysis Unclear [4]
MR008292 BIIB074 BIIB074 metabolite M13 Conjugation - N-carbamoyl glucuronidation UGT1A3 ... [4]
MR008293 BIIB074 BIIB074 metabolite M10 Unclear - Unclear UGT [4]
MR008291 BIIB074 metabolite M14 BIIB074 metabolite M16 Hydrolysis - Amide hydrolysis Unclear [4]
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
UDP-glucuronosyltransferase 1A3 (UGT1A3) DME0041 Homo sapiens
UD13_HUMAN
2.4.1.17
[4]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DME0040 Homo sapiens
UD2B7_HUMAN
2.4.1.17
[4]
References
1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027679)
2 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3 Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
4 Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.